The restructuring of mobile imaging firm Maxum Health resulted in the Dallas-based company postinga net profit of $4.2 million for fiscal 1994 (end-December). Maxumsaid it restructured most of its debt and leasing arrangementsin 1994 and entered into a
The restructuring of mobile imaging firm Maxum Health resulted in the Dallas-based company postinga net profit of $4.2 million for fiscal 1994 (end-December). Maxumsaid it restructured most of its debt and leasing arrangementsin 1994 and entered into a long-term contract with hospital giantColumbia/HCA to run an outpatient imaging center. Maxum beganthe restructuring effort in 1993 (SCAN 3/24/93).
Maxum posted year-end revenues of $45.9 million, up slightlyfrom $45.1 million the year before. The company's net income of$4.2 million represented a major turnaround from the $6.8 millionnet loss recorded in 1993. Much of Maxum's improvement in profitabilitywas attributable to several extraordinary gains, including $3.3million related to extinguishment of debt and $5 million for thesale of its lithotripsy partnership interests. The firm's operatingloss for 1994 stood at $2.8 million, compared to a $6 millionoperating loss in 1993.
Maxum earlier this year partnered with Columbia/HCA to purchaseArlington Diagnostic and Imaging Center in Arlington, VA. Thecenter is jointly owned by the two companies, with Maxum responsiblefor staffing and management.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.